Fig. 6
miR-130a and miR-145 targeted genes and correlation with human cancer. a Kaplan–Meier survival curve (METABRICS data) for breast cancer patients with high & low levels of miR-130a (left), miR-145 (middle), and both miR-130a and 145 (right) in tumor tissues. Log-rank test was used to analyze the survival data. HR hazard ratio with its 95% confidence interval. b Fold change of miR-130a and miR-145 expression in human immature myeloid cells co-cultured with human breast cancer cell line MDA-MB231, miR-93 as a positive control. c qRT-PCR for fold changes of miR-130a (left) and miR-145 (right) in sorted human monocytic and granulocytic subsets from peripheral blood of healthy donors (n = 8) or patients with advanced GI cancer (n = 8). d Correlation of GRB10 levels in human peripheral blood mononuclear cells (PBMCs) (GSE20189) with human lung cancer stages. e Heat map showing a correlation of three key IGF pathway mediators (IGF1R, GRB10, and IRS1) with stages of human lung cancer (GSE20189). f Correlation of GRB10 and TβRII expression levels (key mediators of both IGF and TGFβ pathways) with stages of human lung cancers (GSE20189). Yellow and blue colors indicate increased and decreased expression, respectively. The data were plotted with patients divided into stage I/II vs III /IV groups. The percentage of patients with higher expression level was calculated for each group as indicated. The data are represented as mean ± SEM, and Student’s t test or χ2-square test in (e, f) was performed *p < 0.05, **p < 0.01, ***p < 0.001
